Wacker Biotech is the expert CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid DNA as starting material for viral vectors or mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We can produce at scales from 30 L to 1500 L to serve diverse market needs for R&D, clinical and commercial supply.

We operate five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and USA (San Diego). Complementing our bioprocess development and manufacturing experts at these sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20^th century’s leading chemistry and biochemistry advances. We have 30+ years of experience developing biologics to advance human and animal health.